Development and Standardization of a Furosemide Stress Test to Predict the Severity of Acute Kidney Injury
In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages. We investigated the ability of a furosemide stress test (FST) (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) to predict the development...
Saved in:
Published in | Critical care (London, England) Vol. 17; no. 5; p. R207 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
20.09.2013
BioMed Central |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages.
We investigated the ability of a furosemide stress test (FST) (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) to predict the development of AKIN Stage-III in 2 cohorts of critically ill subjects with early AKI. Cohort 1 was a retrospective cohort who received a FST in the setting of AKI in critically ill patients as part of Southern AKI Network. Cohort 2 was a prospective multicenter group of critically ill patients who received their FST in the setting of early AKI.
We studied 77 subjects; 23 from cohort 1 and 54 from cohort 2; 25 (32.4%) met the primary endpoint of progression to AKIN-III. Subjects with progressive AKI had significantly lower urine output following FST in each of the first 6 hours (p<0.001). The area under the receiver operator characteristic curves for the total urine output over the first 2 hours following FST to predict progression to AKIN-III was 0.87 (p = 0.001). The ideal-cutoff for predicting AKI progression during the first 2 hours following FST was a urine volume of less than 200mls(100ml/hr) with a sensitivity of 87.1% and specificity 84.1%.
The FST in subjects with early AKI serves as a novel assessment of tubular function with robust predictive capacity to identify those patients with severe and progressive AKI. Future studies to validate these findings are warranted. |
---|---|
AbstractList | In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages. We investigated the ability of a furosemide stress test (FST) (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) to predict the development of AKIN Stage-III in 2 cohorts of critically ill subjects with early AKI. Cohort 1 was a retrospective cohort who received a FST in the setting of AKI in critically ill patients as part of Southern AKI Network. Cohort 2 was a prospective multicenter group of critically ill patients who received their FST in the setting of early AKI. We studied 77 subjects; 23 from cohort 1 and 54 from cohort 2; 25 (32.4%) met the primary endpoint of progression to AKIN-III. Subjects with progressive AKI had significantly lower urine output following FST in each of the first 6 hours (p<0.001). The area under the receiver operator characteristic curves for the total urine output over the first 2 hours following FST to predict progression to AKIN-III was 0.87 (p = 0.001). The ideal-cutoff for predicting AKI progression during the first 2 hours following FST was a urine volume of less than 200mls(100ml/hr) with a sensitivity of 87.1% and specificity 84.1%. The FST in subjects with early AKI serves as a novel assessment of tubular function with robust predictive capacity to identify those patients with severe and progressive AKI. Future studies to validate these findings are warranted. INTRODUCTION: In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages. METHODS: We investigated the ability of a furosemide stress test (FST) (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) to predict the development of AKIN Stage-III in 2 cohorts of critically ill subjects with early AKI. Cohort 1 was a retrospective cohort who received a FST in the setting of AKI in critically ill patients as part of Southern AKI Network. Cohort 2 was a prospective multicenter group of critically ill patients who received their FST in the setting of early AKI. RESULTS: We studied 77 subjects; 23 from cohort 1 and 54 from cohort 2; 25 (32.4%) met the primary endpoint of progression to AKIN-III. Subjects with progressive AKI had significantly lower urine output following FST in each of the first 6 hours (p<0.001). The area under the receiver operator characteristic curves for the total urine output over the first 2 hours following FST to predict progression to AKIN-III was 0.87 (p = 0.001). The ideal-cutoff for predicting AKI progression during the first 2 hours following FST was a urine volume of less than 200mls(100ml/hr) with a sensitivity of 87.1% and specificity 84.1%. CONCLUSIONS: The FST in subjects with early AKI serves as a novel assessment of tubular function with robust predictive capacity to identify those patients with severe and progressive AKI. Future studies to validate these findings are warranted. In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages.INTRODUCTIONIn the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages.We investigated the ability of a furosemide stress test (FST) (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) to predict the development of AKIN Stage-III in 2 cohorts of critically ill subjects with early AKI. Cohort 1 was a retrospective cohort who received a FST in the setting of AKI in critically ill patients as part of Southern AKI Network. Cohort 2 was a prospective multicenter group of critically ill patients who received their FST in the setting of early AKI.METHODSWe investigated the ability of a furosemide stress test (FST) (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) to predict the development of AKIN Stage-III in 2 cohorts of critically ill subjects with early AKI. Cohort 1 was a retrospective cohort who received a FST in the setting of AKI in critically ill patients as part of Southern AKI Network. Cohort 2 was a prospective multicenter group of critically ill patients who received their FST in the setting of early AKI.We studied 77 subjects; 23 from cohort 1 and 54 from cohort 2; 25 (32.4%) met the primary endpoint of progression to AKIN-III. Subjects with progressive AKI had significantly lower urine output following FST in each of the first 6 hours (p<0.001). The area under the receiver operator characteristic curves for the total urine output over the first 2 hours following FST to predict progression to AKIN-III was 0.87 (p = 0.001). The ideal-cutoff for predicting AKI progression during the first 2 hours following FST was a urine volume of less than 200mls(100ml/hr) with a sensitivity of 87.1% and specificity 84.1%.RESULTSWe studied 77 subjects; 23 from cohort 1 and 54 from cohort 2; 25 (32.4%) met the primary endpoint of progression to AKIN-III. Subjects with progressive AKI had significantly lower urine output following FST in each of the first 6 hours (p<0.001). The area under the receiver operator characteristic curves for the total urine output over the first 2 hours following FST to predict progression to AKIN-III was 0.87 (p = 0.001). The ideal-cutoff for predicting AKI progression during the first 2 hours following FST was a urine volume of less than 200mls(100ml/hr) with a sensitivity of 87.1% and specificity 84.1%.The FST in subjects with early AKI serves as a novel assessment of tubular function with robust predictive capacity to identify those patients with severe and progressive AKI. Future studies to validate these findings are warranted.CONCLUSIONSThe FST in subjects with early AKI serves as a novel assessment of tubular function with robust predictive capacity to identify those patients with severe and progressive AKI. Future studies to validate these findings are warranted. In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages. We investigated the ability of a furosemide stress test (FST) (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) to predict the development of AKIN Stage-III in 2 cohorts of critically ill subjects with early AKI. Cohort 1 was a retrospective cohort who received a FST in the setting of AKI in critically ill patients as part of Southern AKI Network. Cohort 2 was a prospective multicenter group of critically ill patients who received their FST in the setting of early AKI. We studied 77 subjects; 23 from cohort 1 and 54 from cohort 2; 25 (32.4%) met the primary endpoint of progression to AKIN-III. Subjects with progressive AKI had significantly lower urine output following FST in each of the first 6 hours (p<0.001). The area under the receiver operator characteristic curves for the total urine output over the first 2 hours following FST to predict progression to AKIN-III was 0.87 (p = 0.001). The ideal-cutoff for predicting AKI progression during the first 2 hours following FST was a urine volume of less than 200mls(100ml/hr) with a sensitivity of 87.1% and specificity 84.1%. The FST in subjects with early AKI serves as a novel assessment of tubular function with robust predictive capacity to identify those patients with severe and progressive AKI. Future studies to validate these findings are warranted. |
ArticleNumber | R207 |
Audience | Academic |
Author | Koyner, Jay L Tumlin, James A Brasha-Mitchell, Ermira Shaw, Andrew D Trevino, Sharon A Davison, Danielle L Arthur, John M Seneff, Michael G Kimmel, Paul L Chawla, Lakhmir S |
AuthorAffiliation | 1 Department of Anesthesiology and Critical Care Medicine, George Washington University Medical Center, 900 23rd street, Washington DC, 20037, USA 3 Section of Nephrology, Department of Medicine, University of Chicago, 5841 South Maryland Avenue, Chicago, IL, 60637, USA 7 Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes, Digestive, and Kidney Diseases, NIH, 6707 Democracy Blvd, Bethesda, MD, 20817, USA 4 829 CSB Division of Nephrology, Department of Medicine, Medical University of South Carolina, 96 Jonathan Lucas, Charleston, SC, 250623, USA 5 Department of Anesthesiology, Duke University/Durham VAMC, Durham, DUMC 3094, Durham, NC, 27710, USA 2 Division of Renal Diseases and Hypertension, Department of Medicine, George Washington University Medical Center, 2150 Pennsylvania Avenue, Washington DC, 20037, USA 6 Renal Division, University of Tennessee College of Medicine at Chattanooga, 251 North Lyerly Street, Chattanooga, TN, 37404, USA |
AuthorAffiliation_xml | – name: 3 Section of Nephrology, Department of Medicine, University of Chicago, 5841 South Maryland Avenue, Chicago, IL, 60637, USA – name: 2 Division of Renal Diseases and Hypertension, Department of Medicine, George Washington University Medical Center, 2150 Pennsylvania Avenue, Washington DC, 20037, USA – name: 5 Department of Anesthesiology, Duke University/Durham VAMC, Durham, DUMC 3094, Durham, NC, 27710, USA – name: 7 Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes, Digestive, and Kidney Diseases, NIH, 6707 Democracy Blvd, Bethesda, MD, 20817, USA – name: 6 Renal Division, University of Tennessee College of Medicine at Chattanooga, 251 North Lyerly Street, Chattanooga, TN, 37404, USA – name: 4 829 CSB Division of Nephrology, Department of Medicine, Medical University of South Carolina, 96 Jonathan Lucas, Charleston, SC, 250623, USA – name: 1 Department of Anesthesiology and Critical Care Medicine, George Washington University Medical Center, 900 23rd street, Washington DC, 20037, USA |
Author_xml | – sequence: 1 givenname: Lakhmir S surname: Chawla fullname: Chawla, Lakhmir S – sequence: 2 givenname: Danielle L surname: Davison fullname: Davison, Danielle L – sequence: 3 givenname: Ermira surname: Brasha-Mitchell fullname: Brasha-Mitchell, Ermira – sequence: 4 givenname: Jay L surname: Koyner fullname: Koyner, Jay L – sequence: 5 givenname: John M surname: Arthur fullname: Arthur, John M – sequence: 6 givenname: Andrew D surname: Shaw fullname: Shaw, Andrew D – sequence: 7 givenname: James A surname: Tumlin fullname: Tumlin, James A – sequence: 8 givenname: Sharon A surname: Trevino fullname: Trevino, Sharon A – sequence: 9 givenname: Paul L surname: Kimmel fullname: Kimmel, Paul L – sequence: 10 givenname: Michael G surname: Seneff fullname: Seneff, Michael G |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24053972$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kl1rFDEUhoNUbLuK_0AGvNCbqclkMpn1Qliq1WJBwXodMslJm2Um2SYzhfXXe9Zdy64fBJJDznPe5HyckqMQAxDynNEzxtrmjTGMUyYekRPGm7psBRdHe_YxOc15SSmTbcOfkOOqpoLPZXVClu_hHvq4GiCMhQ62-DbirpP1P_ToYyiiK3RxMaWYYfAW0J8g5-Ia8liMsfiawHqD5i26UCr5cb2JWZhphOKztwHWxWVYTmn9lDx2us_wbHfOyPeLD9fnn8qrLx8vzxdXZScEH0tBuRTMwtyZrgHTaqa1c6axzLXCdlzyzlndOll1TT1nc9ox6aizDGrWmablM_Juq7uaugGswcyS7tUq-UGntYraq0NP8LfqJt4rLIoUWJgZebsV6Hz8j8Chx8RB7TqAwa93r6d4N2GV1OCzgb7XAeKUFRO1kBIzpYi-3KI3ugflg4uoZja4WgheS9lWokLq7B8ULosNMTgGzuP9QcCL_fwf_v276Qi82gIGu5oTuAeEUbUZp71kyj9I48dfc4F_8P1f_E9W4c3P |
CitedBy_id | crossref_primary_10_2215_CJN_05450522 crossref_primary_10_1016_j_jtcvs_2019_11_137 crossref_primary_10_1186_s12967_024_05279_4 crossref_primary_10_1038_nrneph_2017_2 crossref_primary_10_1097_MCC_0000000000000746 crossref_primary_10_1093_ndt_gfz188 crossref_primary_10_1097_CCM_0000000000001823 crossref_primary_10_1177_2150135115623289 crossref_primary_10_12677_ACM_2023_1361432 crossref_primary_10_1038_s41598_023_31757_8 crossref_primary_10_1515_cclm_2021_0040 crossref_primary_10_1007_s00467_023_06161_z crossref_primary_10_1007_s40620_017_0416_8 crossref_primary_10_1155_2015_729075 crossref_primary_10_5492_wjccm_v10_i6_310 crossref_primary_10_1111_aas_13599 crossref_primary_10_23876_j_krcp_23_284 crossref_primary_10_1186_s13054_015_0850_8 crossref_primary_10_1038_s41581_018_0054_y crossref_primary_10_2215_CJN_14181021 crossref_primary_10_1053_j_ackd_2018_03_001 crossref_primary_10_34067_KID_0001342022 crossref_primary_10_1007_s00134_021_06595_9 crossref_primary_10_1007_s10741_021_10124_7 crossref_primary_10_1007_s11560_019_00381_x crossref_primary_10_1053_j_ackd_2020_08_002 crossref_primary_10_1093_ckj_sfy022 crossref_primary_10_3390_diseases10020020 crossref_primary_10_17116_anaesthesiology20210516 crossref_primary_10_1007_s00134_018_5502_4 crossref_primary_10_1016_j_jcrc_2024_154901 crossref_primary_10_1007_s40620_019_00614_1 crossref_primary_10_1007_s40746_016_0047_7 crossref_primary_10_1007_s00467_023_06133_3 crossref_primary_10_1053_j_ackd_2016_03_007 crossref_primary_10_1093_burnst_tkad008 crossref_primary_10_1097_ALN_0000000000005215 crossref_primary_10_1053_j_ackd_2016_03_001 crossref_primary_10_1016_j_jcrc_2019_04_011 crossref_primary_10_3390_jcm9041104 crossref_primary_10_1038_s41598_024_83878_3 crossref_primary_10_3389_fmed_2021_697055 crossref_primary_10_5005_jp_journals_10071_23381 crossref_primary_10_1016_j_jcrc_2018_02_009 crossref_primary_10_1016_j_kint_2020_04_020 crossref_primary_10_1007_s00101_023_01338_5 crossref_primary_10_1186_s40697_016_0099_4 crossref_primary_10_1007_s40620_022_01534_3 crossref_primary_10_34067_KID_0001262022 crossref_primary_10_1007_s00467_016_3539_6 crossref_primary_10_1007_s12098_024_05401_w crossref_primary_10_1053_j_ackd_2017_05_003 crossref_primary_10_1007_s00134_022_06909_5 crossref_primary_10_1007_s00134_017_4832_y crossref_primary_10_1097_PCC_0000000000001822 crossref_primary_10_1038_s41598_024_54926_9 crossref_primary_10_1007_s40620_024_01949_0 crossref_primary_10_1055_a_2187_3045 crossref_primary_10_1681_ASN_2014121160 crossref_primary_10_1111_aor_14705 crossref_primary_10_1186_s12911_021_01740_2 crossref_primary_10_1016_j_semnephrol_2024_151512 crossref_primary_10_2215_CJN_11070821 crossref_primary_10_1177_0885066618824531 crossref_primary_10_1186_s13054_018_2192_9 crossref_primary_10_7759_cureus_53982 crossref_primary_10_1016_j_medin_2016_12_004 crossref_primary_10_1542_neo_23_3_e189 crossref_primary_10_1007_s00063_017_0400_z crossref_primary_10_1053_j_jvca_2018_03_017 crossref_primary_10_1097_MNH_0000000000000292 crossref_primary_10_1016_j_ekir_2018_03_004 crossref_primary_10_1007_s40124_018_0184_5 crossref_primary_10_1053_j_jvca_2025_01_019 crossref_primary_10_1097_AIA_0000000000000224 crossref_primary_10_1016_j_jcrc_2024_154929 crossref_primary_10_1186_s13054_022_04121_x crossref_primary_10_1177_1179560317730032 crossref_primary_10_1007_s00134_017_4792_2 crossref_primary_10_3389_fneph_2022_879766 crossref_primary_10_1016_j_jcrc_2020_07_004 crossref_primary_10_1007_s40620_018_0539_6 crossref_primary_10_1016_j_athoracsur_2017_03_015 crossref_primary_10_1186_s40001_023_01092_9 crossref_primary_10_1373_clinchem_2018_288068 crossref_primary_10_1016_j_kint_2019_05_026 crossref_primary_10_1097_PCC_0000000000002933 crossref_primary_10_1007_s00063_016_0159_7 crossref_primary_10_1155_2014_365186 crossref_primary_10_2169_naika_108_1212 crossref_primary_10_1186_s13054_018_2021_1 crossref_primary_10_1186_s13613_015_0095_3 crossref_primary_10_1007_s11255_024_04271_7 crossref_primary_10_1097_MNH_0000000000000707 crossref_primary_10_1590_2175_8239_jbn_2021_0003 crossref_primary_10_1159_000533478 crossref_primary_10_1186_s12944_015_0169_0 crossref_primary_10_1007_s00467_023_05920_2 crossref_primary_10_5858_arpa_2021_0411_OA crossref_primary_10_1016_j_pcl_2022_08_003 crossref_primary_10_1055_a_2183_2448 crossref_primary_10_1097_CCM_0000000000005849 crossref_primary_10_1097_JTCCM_D_24_00003 crossref_primary_10_1080_0886022X_2021_1906701 crossref_primary_10_1152_physiol_00011_2023 crossref_primary_10_1007_s12098_023_04483_2 crossref_primary_10_1016_j_medine_2016_09_003 crossref_primary_10_1159_000501315 crossref_primary_10_1007_s00134_017_4841_x crossref_primary_10_1053_j_ajkd_2015_12_033 crossref_primary_10_1097_MCC_0000000000000891 crossref_primary_10_1186_s12882_020_01721_z crossref_primary_10_1161_CIRCHEARTFAILURE_120_008166 crossref_primary_10_1007_s00063_018_0413_2 crossref_primary_10_1371_journal_pone_0246595 crossref_primary_10_1007_s00467_021_04940_0 crossref_primary_10_1155_2016_6805169 crossref_primary_10_3390_ijms21093086 crossref_primary_10_1111_nep_14132 crossref_primary_10_1080_0886022X_2022_2151468 crossref_primary_10_1007_s00063_017_0346_1 crossref_primary_10_1590_2175_8239_jbn_2021_e010 crossref_primary_10_1080_1354750X_2017_1387934 crossref_primary_10_2215_CJN_12001017 crossref_primary_10_1007_s00467_023_06156_w crossref_primary_10_1097_CCE_0000000000000112 crossref_primary_10_1016_j_jcrc_2017_07_030 crossref_primary_10_1007_s11560_024_00716_3 crossref_primary_10_1186_s13054_020_02912_8 crossref_primary_10_1016_j_medine_2017_03_005 crossref_primary_10_51847_a6dBTglkCE crossref_primary_10_47373_rfcs_2021_v23_1924 crossref_primary_10_3928_19382359_20180619_02 crossref_primary_10_36290_aim_2019_074 crossref_primary_10_1016_j_bpg_2017_03_004 crossref_primary_10_1186_s13741_024_00416_5 crossref_primary_10_1213_ANE_0000000000003741 crossref_primary_10_1007_s00134_018_5159_z crossref_primary_10_1016_j_athoracsur_2023_07_011 crossref_primary_10_3390_kidneydial2010008 crossref_primary_10_1097_MCC_0000000000001212 crossref_primary_10_1007_s12098_019_03096_y crossref_primary_10_1016_j_ccc_2015_06_001 crossref_primary_10_1016_j_ekir_2016_04_005 crossref_primary_10_7759_cureus_65824 crossref_primary_10_3389_fvets_2021_659960 crossref_primary_10_1159_000446666 crossref_primary_10_1681_ASN_2014060535 crossref_primary_10_1111_apha_14181 crossref_primary_10_1016_j_cveq_2019_12_003 crossref_primary_10_1155_2019_6948710 crossref_primary_10_1186_s13613_018_0355_0 crossref_primary_10_1007_s00467_023_05885_2 crossref_primary_10_1016_j_jfma_2021_02_013 crossref_primary_10_1016_j_ccc_2015_06_013 crossref_primary_10_1055_s_0041_1732447 crossref_primary_10_1016_j_ccc_2015_06_012 crossref_primary_10_1007_s12630_020_01894_z crossref_primary_10_1016_j_jtcvs_2018_12_076 crossref_primary_10_1016_j_jacc_2020_06_070 crossref_primary_10_1016_j_rmu_2017_10_004 crossref_primary_10_1016_j_trsl_2020_11_011 crossref_primary_10_4103_ajpn_ajpn_6_22 crossref_primary_10_1590_1806_9282_66_s1_68 crossref_primary_10_1016_j_siny_2016_12_001 crossref_primary_10_1016_j_plabm_2022_e00272 crossref_primary_10_1097_CCM_0000000000003738 crossref_primary_10_1186_cc13871 crossref_primary_10_1007_s00134_023_07171_z crossref_primary_10_1007_s40140_019_00325_0 crossref_primary_10_1038_s41581_021_00410_w crossref_primary_10_1097_CCM_0000000000003862 crossref_primary_10_1016_j_medin_2016_05_009 crossref_primary_10_1097_PCC_0000000000000461 crossref_primary_10_1080_0886022X_2023_2298900 crossref_primary_10_5005_jp_journals_10071_24865 crossref_primary_10_5005_jp_journals_10071_24862 crossref_primary_10_1016_j_mayocp_2019_01_040 crossref_primary_10_1016_j_ccc_2020_11_005 crossref_primary_10_1159_000449235 crossref_primary_10_1007_s40620_022_01335_8 crossref_primary_10_1371_journal_pone_0196088 crossref_primary_10_23736_S0375_9393_21_14942_9 crossref_primary_10_1038_s41390_021_01452_3 crossref_primary_10_1159_000447979 crossref_primary_10_1093_ckj_sfx003 crossref_primary_10_1371_journal_pone_0169305 crossref_primary_10_1016_j_suc_2017_07_004 crossref_primary_10_1097_ALN_0000000000004746 crossref_primary_10_1159_000529068 crossref_primary_10_1681_ASN_2014070724 crossref_primary_10_1164_rccm_201604_0799OC crossref_primary_10_5005_jp_journals_10071_23911 crossref_primary_10_1038_s41581_024_00918_x crossref_primary_10_1007_s11897_019_00425_2 crossref_primary_10_1186_s13613_024_01387_y crossref_primary_10_1186_s13613_019_0509_8 crossref_primary_10_1093_bja_aeu299 crossref_primary_10_1007_s40620_021_01162_3 crossref_primary_10_1371_journal_pone_0204920 crossref_primary_10_1055_a_1518_5404 crossref_primary_10_1007_s00740_019_00298_0 crossref_primary_10_3390_medicina58030340 crossref_primary_10_1016_S0140_6736_24_02385_7 crossref_primary_10_1186_s13613_017_0260_y crossref_primary_10_1016_j_jtcvs_2019_01_038 crossref_primary_10_1016_S1441_2772_23_00786_X crossref_primary_10_1007_s00101_016_0259_z crossref_primary_10_1016_j_mayocp_2019_12_034 crossref_primary_10_1186_s13613_016_0168_y crossref_primary_10_1097_CCM_0000000000003701 crossref_primary_10_14814_phy2_15453 crossref_primary_10_7759_cureus_44408 crossref_primary_10_1093_ndt_gfx023 crossref_primary_10_1097_MCC_0000000000001101 crossref_primary_10_1542_pir_2021_005438 crossref_primary_10_1111_sdi_12773 crossref_primary_10_1080_10408363_2023_2242481 crossref_primary_10_1136_bmjopen_2023_074046 crossref_primary_10_1080_0886022X_2024_2404237 crossref_primary_10_3904_kjm_2019_94_4_315 crossref_primary_10_1159_000538898 crossref_primary_10_1097_MCC_0000000000000257 crossref_primary_10_3238_arztebl_2019_0833 crossref_primary_10_1159_000441283 crossref_primary_10_3389_fphys_2022_913580 crossref_primary_10_1016_j_bpa_2017_08_006 crossref_primary_10_1016_j_ekir_2017_03_015 crossref_primary_10_1097_PCC_0000000000001478 crossref_primary_10_3389_fvets_2023_1195743 crossref_primary_10_1186_s13613_024_01349_4 crossref_primary_10_1007_s00467_023_05891_4 crossref_primary_10_1007_s00467_024_06387_5 crossref_primary_10_1016_j_aan_2023_06_005 crossref_primary_10_4103_ijccm_IJCCM_295_18 crossref_primary_10_1007_s00134_024_07441_4 crossref_primary_10_1186_s40560_017_0251_y crossref_primary_10_3389_fped_2018_00306 crossref_primary_10_1016_j_anclin_2022_10_004 crossref_primary_10_3390_jcm11154576 |
Cites_doi | 10.1038/nrneph.2011.216 10.1001/jama.288.20.2547 10.2215/CJN.04871107 10.1152/ajplegacy.1970.219.1.114 10.1038/ki.1989.246 10.2215/CJN.07201009 10.1161/01.RES.37.5.558 10.1681/ASN.2011090907 10.1159/000102086 10.1097/MCC.0b013e32833e2fa4 10.1186/cc5713 10.1007/BF01709751 10.2215/CJN.04960511 10.1097/00003246-198108000-00008 10.1152/ajplegacy.1973.225.1.119 10.7326/0003-4819-130-6-199903160-00002 10.1152/ajplegacy.1975.229.1.93 10.1159/000102085 10.2215/CJN.00740110 10.1038/ki.1994.132 10.1124/jpet.103.059139 10.1097/00000658-197303000-00001 10.1038/ki.1979.120 10.1002/cpt1979254435 10.2215/CJN.06280612 10.1111/j.1365-2044.2009.06228.x 10.1053/j.ajkd.2008.02.371 10.1159/000166605 10.1186/1745-6215-11-50 10.1038/ki.2011.379 10.1681/ASN.2012080800 10.1016/S0140-6736(11)61454-2 10.1172/JCI113498 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2013 BioMed Central Ltd. Copyright © 2013 Chawla et al. licensee BioMed Central Ltd. 2013 Chawla et al. licensee BioMed Central Ltd. |
Copyright_xml | – notice: COPYRIGHT 2013 BioMed Central Ltd. – notice: Copyright © 2013 Chawla et al. licensee BioMed Central Ltd. 2013 Chawla et al. licensee BioMed Central Ltd. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1186/cc13015 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1364-8535 1466-609X |
EndPage | R207 |
ExternalDocumentID | PMC4057505 oai_biomedcentral_com_cc13015 A534778252 24053972 10_1186_cc13015 |
Genre | Multicenter Study Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: L30 DK084760 – fundername: NIDDK NIH HHS grantid: R01 DK080234 – fundername: NIDDK NIH HHS grantid: K23 DK081616 – fundername: NIDDK NIH HHS grantid: K23DK081616 |
GroupedDBID | --- 0R~ 29F 2WC 4.4 53G 5GY 5VS 6J9 6PF AAFWJ AAJSJ AASML AAWTL AAYXX ACGFS ACJQM ADBBV ADUKV AEGXH AENEX AFPKN AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BFQNJ BMC C6C CITATION CS3 DIK E3Z EBD EBLON EBS EJD EMOBN F5P GROUPED_DOAJ GX1 H13 HYE IAO IHR INH INR ITC KQ8 OK1 PQQKQ RBZ ROL RPM RSV SJN SMD SOJ SV3 TR2 U2A WOQ YOC CGR CUY CVF ECM EIF NPM 7X8 -5E -5G -BR 3V. 7X7 88E 8FI 8FJ ABUWG ABVAZ ACRMQ ADINQ AFGXO AFKRA AFNRJ BENPR BPHCQ BVXVI C1A C24 CCPQU FYUFA HMCUK M1P O5R O5S PIMPY PROAC PSQYO UKHRP 5PM |
ID | FETCH-LOGICAL-b553t-503751de9fcb6ec8a1aaffc6d1f85db373bfda8f72b649190b17f0fd1e41bc683 |
IEDL.DBID | RBZ |
ISSN | 1364-8535 1466-609X |
IngestDate | Thu Aug 21 14:11:44 EDT 2025 Wed May 22 07:13:49 EDT 2024 Fri Jul 11 01:09:19 EDT 2025 Tue Jun 17 22:05:01 EDT 2025 Tue Jun 10 21:01:21 EDT 2025 Thu Apr 03 06:49:24 EDT 2025 Tue Jul 01 03:54:27 EDT 2025 Thu Apr 24 23:01:52 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
License | This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b553t-503751de9fcb6ec8a1aaffc6d1f85db373bfda8f72b649190b17f0fd1e41bc683 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | http://dx.doi.org/10.1186/cc13015 |
PMID | 24053972 |
PQID | 1545775530 |
PQPubID | 23479 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4057505 biomedcentral_primary_oai_biomedcentral_com_cc13015 proquest_miscellaneous_1545775530 gale_infotracmisc_A534778252 gale_infotracacademiconefile_A534778252 pubmed_primary_24053972 crossref_primary_10_1186_cc13015 crossref_citationtrail_10_1186_cc13015 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2013-09-20 |
PublicationDateYYYYMMDD | 2013-09-20 |
PublicationDate_xml | – month: 09 year: 2013 text: 2013-09-20 day: 20 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Critical care (London, England) |
PublicationTitleAlternate | Crit Care |
PublicationYear | 2013 |
Publisher | BioMed Central Ltd BioMed Central |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central |
References | JL Koyner (2976_CR28) 2010; 5 NR Loon (2976_CR19) 1989; 36 DC Brater (2976_CR15) 1979; 25 N Gibney (2976_CR4) 2008; 3 RH Bowman (2976_CR12) 1975; 229 WJ Arendshorst (2976_CR23) 1975; 37 SN Heyman (2976_CR31) 1994; 45 JE Bird (2976_CR24) 1988; 81 P Chennavasin (2976_CR25) 1979; 16 AS Levey (2976_CR22) 1999; 130 WA Knaus (2976_CR20) 1981; 9 H Hasannejad (2976_CR11) 2004; 308 SL Goldstein (2976_CR33) 2010; 5 JH Dirks (2976_CR14) 1970; 219 JV Bonventre (2976_CR8) 2007; 156 R Bellomo (2976_CR1) 2012; 380 VF Seabra (2976_CR5) 2008; 52 P Devarajan (2976_CR9) 2007; 156 RL Mehta (2976_CR29) 2002; 288 SG Coca (2976_CR2) 2012; 81 RK Hsu (2976_CR3) 2013; 24 M Burg (2976_CR13) 1973; 225 JL Alge (2976_CR17) 2013; 8 JL Vincent (2976_CR21) 1996; 22 LS Chawla (2976_CR7) 2012; 8 SM Bagshaw (2976_CR32) 2010; 11 LS Chawla (2976_CR18) 2008; 110 SM Baek (2976_CR26) 1973; 177 RL Mehta (2976_CR16) 2007; 11 K Doi (2976_CR10) 2010; 16 KM Ho (2976_CR30) 2010; 65 IE Hall (2976_CR27) 2011; 6 JL Koyner (2976_CR6) 2012; 23 7261642 - Crit Care Med. 1981 Aug;9(8):591-7 22383693 - J Am Soc Nephrol. 2012 May;23(5):905-14 23222124 - J Am Soc Nephrol. 2013 Jan;24(1):37-42 2811065 - Kidney Int. 1989 Oct;36(4):682-9 428188 - Clin Pharmacol Ther. 1979 Apr;25(4):435-9 22034509 - Clin J Am Soc Nephrol. 2011 Dec;6(12):2740-9 4714389 - Am J Physiol. 1973 Jul;225(1):119-24 4692111 - Ann Surg. 1973 Mar;177(3):253-8 8844239 - Intensive Care Med. 1996 Jul;22(7):707-10 513505 - Kidney Int. 1979 Aug;16(2):187-95 22617274 - Lancet. 2012 Aug 25;380(9843):756-66 17464129 - Contrib Nephrol. 2007;156:203-12 18953176 - Nephron Clin Pract. 2008;110(3):c145-50 10075613 - Ann Intern Med. 1999 Mar 16;130(6):461-70 23143504 - Clin J Am Soc Nephrol. 2013 Feb;8(2):184-93 2835399 - J Clin Invest. 1988 May;81(5):1630-8 20085566 - Anaesthesia. 2010 Mar;65(3):283-93 18562058 - Am J Kidney Dis. 2008 Aug;52(2):272-84 14610216 - J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9 17331245 - Crit Care. 2007;11(2):R31 25473657 - Crit Care. 2014;18(3):429 1192555 - Circ Res. 1975 Nov;37(5):558-68 22249777 - Nat Rev Nephrol. 2012 Feb;8(2):68-70 12444861 - JAMA. 2002 Nov 27;288(20):2547-53 17464130 - Contrib Nephrol. 2007;156:213-9 20736829 - Curr Opin Crit Care. 2010 Dec;16(6):545-9 5424836 - Am J Physiol. 1970 Jul;219(1):114-21 20798258 - Clin J Am Soc Nephrol. 2010 Dec;5(12):2154-65 20459801 - Trials. 2010;11:50 20299370 - Clin J Am Soc Nephrol. 2010 May;5(5):943-9 1147061 - Am J Physiol. 1975 Jul;229(1):93-8 25033085 - Crit Care. 2014;18(3):429 22113526 - Kidney Int. 2012 Mar;81(5):442-8 8007601 - Kidney Int. 1994 Apr;45(4):981-5 18322044 - Clin J Am Soc Nephrol. 2008 May;3(3):876-80 |
References_xml | – volume: 8 start-page: 68 year: 2012 ident: 2976_CR7 publication-title: Nat Rev Nephrol doi: 10.1038/nrneph.2011.216 – volume: 288 start-page: 2547 year: 2002 ident: 2976_CR29 publication-title: Jama doi: 10.1001/jama.288.20.2547 – volume: 3 start-page: 876 year: 2008 ident: 2976_CR4 publication-title: Clin J Am Soc Nephrol doi: 10.2215/CJN.04871107 – volume: 219 start-page: 114 year: 1970 ident: 2976_CR14 publication-title: Am J Physiol doi: 10.1152/ajplegacy.1970.219.1.114 – volume: 36 start-page: 682 year: 1989 ident: 2976_CR19 publication-title: Kidney Int doi: 10.1038/ki.1989.246 – volume: 5 start-page: 943 year: 2010 ident: 2976_CR33 publication-title: Clin J Am Soc Nephrol doi: 10.2215/CJN.07201009 – volume: 37 start-page: 558 year: 1975 ident: 2976_CR23 publication-title: Circ Res doi: 10.1161/01.RES.37.5.558 – volume: 23 start-page: 905 year: 2012 ident: 2976_CR6 publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2011090907 – volume: 156 start-page: 213 year: 2007 ident: 2976_CR8 publication-title: Contrib Nephrol doi: 10.1159/000102086 – volume: 16 start-page: 545 year: 2010 ident: 2976_CR10 publication-title: Curr Opin Crit Care doi: 10.1097/MCC.0b013e32833e2fa4 – volume: 11 start-page: R31 year: 2007 ident: 2976_CR16 publication-title: Crit Care doi: 10.1186/cc5713 – volume: 22 start-page: 707 year: 1996 ident: 2976_CR21 publication-title: Intensive Care Med doi: 10.1007/BF01709751 – volume: 6 start-page: 2740 year: 2011 ident: 2976_CR27 publication-title: Clin J Am Soc Nephrol doi: 10.2215/CJN.04960511 – volume: 9 start-page: 591 year: 1981 ident: 2976_CR20 publication-title: Crit Care Med doi: 10.1097/00003246-198108000-00008 – volume: 225 start-page: 119 year: 1973 ident: 2976_CR13 publication-title: Am J Physiol doi: 10.1152/ajplegacy.1973.225.1.119 – volume: 130 start-page: 461 year: 1999 ident: 2976_CR22 publication-title: Ann Intern Med doi: 10.7326/0003-4819-130-6-199903160-00002 – volume: 229 start-page: 93 year: 1975 ident: 2976_CR12 publication-title: Am J Physiol doi: 10.1152/ajplegacy.1975.229.1.93 – volume: 156 start-page: 203 year: 2007 ident: 2976_CR9 publication-title: Contrib Nephrol doi: 10.1159/000102085 – volume: 5 start-page: 2154 year: 2010 ident: 2976_CR28 publication-title: Clin J Am Soc Nephrol doi: 10.2215/CJN.00740110 – volume: 45 start-page: 981 year: 1994 ident: 2976_CR31 publication-title: Kidney Int doi: 10.1038/ki.1994.132 – volume: 308 start-page: 1021 year: 2004 ident: 2976_CR11 publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.103.059139 – volume: 177 start-page: 253 year: 1973 ident: 2976_CR26 publication-title: Ann Surg doi: 10.1097/00000658-197303000-00001 – volume: 16 start-page: 187 year: 1979 ident: 2976_CR25 publication-title: Kidney Int doi: 10.1038/ki.1979.120 – volume: 25 start-page: 435 year: 1979 ident: 2976_CR15 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt1979254435 – volume: 8 start-page: 184 year: 2013 ident: 2976_CR17 publication-title: Clin J Am Soc Nephrol doi: 10.2215/CJN.06280612 – volume: 65 start-page: 283 year: 2010 ident: 2976_CR30 publication-title: Anaesthesia doi: 10.1111/j.1365-2044.2009.06228.x – volume: 52 start-page: 272 year: 2008 ident: 2976_CR5 publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2008.02.371 – volume: 110 start-page: c145 year: 2008 ident: 2976_CR18 publication-title: Nephron Clin Pract doi: 10.1159/000166605 – volume: 11 start-page: 50 year: 2010 ident: 2976_CR32 publication-title: Trials doi: 10.1186/1745-6215-11-50 – volume: 81 start-page: 442 year: 2012 ident: 2976_CR2 publication-title: Kidney Int doi: 10.1038/ki.2011.379 – volume: 24 start-page: 37 year: 2013 ident: 2976_CR3 publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2012080800 – volume: 380 start-page: 756 year: 2012 ident: 2976_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(11)61454-2 – volume: 81 start-page: 1630 year: 1988 ident: 2976_CR24 publication-title: J Clin Invest doi: 10.1172/JCI113498 – reference: 20459801 - Trials. 2010;11:50 – reference: 22249777 - Nat Rev Nephrol. 2012 Feb;8(2):68-70 – reference: 4692111 - Ann Surg. 1973 Mar;177(3):253-8 – reference: 7261642 - Crit Care Med. 1981 Aug;9(8):591-7 – reference: 14610216 - J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9 – reference: 20085566 - Anaesthesia. 2010 Mar;65(3):283-93 – reference: 23222124 - J Am Soc Nephrol. 2013 Jan;24(1):37-42 – reference: 17464129 - Contrib Nephrol. 2007;156:203-12 – reference: 20736829 - Curr Opin Crit Care. 2010 Dec;16(6):545-9 – reference: 2811065 - Kidney Int. 1989 Oct;36(4):682-9 – reference: 2835399 - J Clin Invest. 1988 May;81(5):1630-8 – reference: 8844239 - Intensive Care Med. 1996 Jul;22(7):707-10 – reference: 1147061 - Am J Physiol. 1975 Jul;229(1):93-8 – reference: 17331245 - Crit Care. 2007;11(2):R31 – reference: 22383693 - J Am Soc Nephrol. 2012 May;23(5):905-14 – reference: 20798258 - Clin J Am Soc Nephrol. 2010 Dec;5(12):2154-65 – reference: 428188 - Clin Pharmacol Ther. 1979 Apr;25(4):435-9 – reference: 513505 - Kidney Int. 1979 Aug;16(2):187-95 – reference: 23143504 - Clin J Am Soc Nephrol. 2013 Feb;8(2):184-93 – reference: 22034509 - Clin J Am Soc Nephrol. 2011 Dec;6(12):2740-9 – reference: 18562058 - Am J Kidney Dis. 2008 Aug;52(2):272-84 – reference: 25473657 - Crit Care. 2014;18(3):429 – reference: 5424836 - Am J Physiol. 1970 Jul;219(1):114-21 – reference: 8007601 - Kidney Int. 1994 Apr;45(4):981-5 – reference: 18322044 - Clin J Am Soc Nephrol. 2008 May;3(3):876-80 – reference: 1192555 - Circ Res. 1975 Nov;37(5):558-68 – reference: 25033085 - Crit Care. 2014;18(3):429 – reference: 17464130 - Contrib Nephrol. 2007;156:213-9 – reference: 18953176 - Nephron Clin Pract. 2008;110(3):c145-50 – reference: 20299370 - Clin J Am Soc Nephrol. 2010 May;5(5):943-9 – reference: 12444861 - JAMA. 2002 Nov 27;288(20):2547-53 – reference: 22113526 - Kidney Int. 2012 Mar;81(5):442-8 – reference: 22617274 - Lancet. 2012 Aug 25;380(9843):756-66 – reference: 10075613 - Ann Intern Med. 1999 Mar 16;130(6):461-70 – reference: 4714389 - Am J Physiol. 1973 Jul;225(1):119-24 |
SSID | ssj0017863 |
Score | 2.535681 |
Snippet | In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages.
We investigated the... Introduction In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages. Methods... In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages. We investigated the... In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages.INTRODUCTIONIn the... INTRODUCTION: In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages. METHODS:... |
SourceID | pubmedcentral biomedcentral proquest gale pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | R207 |
SubjectTerms | Acute Kidney Injury - diagnosis Acute Kidney Injury - urine Acute renal failure Aged Cohort Studies Diagnosis Diuretics Exercise Test - standards Exercise Test - trends Exercise tests Female Furosemide Health aspects Humans Male Middle Aged Pilot Projects Predictive Value of Tests Prognosis Prospective Studies Retrospective Studies Severity of Illness Index |
Title | Development and Standardization of a Furosemide Stress Test to Predict the Severity of Acute Kidney Injury |
URI | https://www.ncbi.nlm.nih.gov/pubmed/24053972 https://www.proquest.com/docview/1545775530 http://dx.doi.org/10.1186/cc13015 https://pubmed.ncbi.nlm.nih.gov/PMC4057505 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEA-lgvgifnu2lhREnxY3u_l8PMWjKhWhLRRfQj7plXZP6t5D_3tn9vbOS_XJt4VJhjCTyfxmk5kh5E3OIgiZVeVinSquEq-M165yJiipQqxNg_nOx9_k0Rn_ci7Od8jhv2_wmZbvQ4BjFtPI7zUc4jgMyD_82FwUKD00S2Ot5BV4HrHKi92eeCeT_apwQHeP4S0_VL6R3HI6s0fk4YgW6XSl3sdkJ3VPyP3j8T78KbncevNDXRfpyfhnYMyupItMHZ1hycp0PY-JngypIfQUFkH7Bf1-g6zg8wJIwAo72eGcaVj2iX6dxy7d0s_dJQj-GTmbfTr9eFSN3RMqL0TbVwK727KYTA5epqAdcy7nICPLWkTfqtbn6HRWjZfcAC7wTOU6R5Y480Hq9jnZ7RZdeklobUKGsEYrE2vuOIR4DsIoFTRzpq2dmpC2ELH9uaqUYbF2dUkBM7KjYibk7VoRNowFybEvxpUdAhMt_wykm4Frzn8NeYeatGiVwCO4MbkA1o_1rexUtFwBGBLNhOwXI8GaQkE-XO8FiyR8gtalxfKXRaypFHZZmpAXq72xWQ3AIgHADmarYtcUgigp3fxiKOY9AOZavPovEe6RB83QnsPAabdPdvubZXoNIKn3B8PPhYPBWH4DVuQVrA |
linkProvider | BioMedCentral |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxELZQkYAL4t1AASMhOC3sZtevY0BEKW0qpKZSxcXyU00VNqjdHPrvGXudsC43biuNbVkez3i8nm8-hN57TwyhnhXKlq5omGsKobkqlDCMMmNLMQ545_kJnZ0138_JeeI5DVgYkwr8h7ynT0ME-iq67W22WG_snH42BpxwAJnfZYSwCOD68nP3jMB4pFKratoUcC6RHjU77HgL577KjqfbTnpwSuUZlIMjafoIPUyxJJ70s32M7rj2Cbo3T6_lT9HlICMIq9bi0_TfIGEv8dpjhaehoKX7tbQOn0bgCF7AJHC3xj-uwlDweQEiGCrw3IU-E7PpHD5a2tbd4MP2EtTyDJ1Nvy2-zorErVBoQuquIIH7trJOeKOpM1xVSnlvqK08J1bXrNbeKu7ZWNNGQNSgK-ZLbyvXVNpQXj9He-26dfsIl8J4uPRwJmzZqAYugAouWczwSom6VGyE6myJ5e--joYMla1zCahYJsWM0IetIqRJ5coDa8ZKxmsLp38b4l3D7cj_NPkYNCmDzcIYRiXoAcw_VL-SE1I3DEIlMh6hg6wl2JrJxO-2e0EGUUhQa916cy1DJMpY4GAaoRf93tjNBoImAmEf9GbZrskWIpe0y4tY6juG0yV5-V9L-Bbdny3mx_L48OToFXowjkQeAvziAdrrrjbuNYRTnX4TTeYPlY8j3g |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQkSouiDcLpTUSglNosokfOS6lq5bSqqKtVHGx_FS3LNmqZA_8e2YS7xKXG7dIY1uWZ8Yex_PNR8i7EJhlPIhMu9xnlfBVVhupM11bwYV1eT1GvPPxCT-4qL5csssBit_GAv-Y9_RxiECfd9s2fNgfuzcu9N4u-a61sAsjyvy-YEwgh8G3T9_X7whCdlxqRcmrDA4m1sNmhx3vAN3nyfl0d5ceHFNpCuXgTJo-Ig9jMEknvfYfk3u-eUI2j-Nz-VNyPUgJorpx9Cz-OIjgS7oIVNMpVrT0P2fO07MOOULPYRK0XdDTWxwKPq9ABEMh0R32mdhl6-nRzDX-Nz1srkEvz8jFdP987yCL5AqZYaxsM4bkt4XzdbCGeyt1oXUIlrsiSOZMKUoTnJZBjA2vaggbTCFCHlzhq8JYLsvnZKNZNP4loXltA9x6pKhdXukKboAablnCykLXZa7FiJTJEqubvpCGwtLWqQR0rKJiRuT9ShHKxnrlSJsxV929RfK_Dem64Wrkf5p8QE0qdFo0IR2xBzB_LH-lJqysBMRKbDwiW0lLcDabiN-ubEGhCDPUGr9Y_lIYigqBJEwj8qK3jfVsIGpiEPdBb5FYTbIQqaSZXXW1vrt4Omev_msJd8jm6eep-np4cvSaPBh3RB417ItbZKO9Xfo3EE61ZrvzmD8M9SOp |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+and+Standardization+of+a+Furosemide+Stress+Test+to+Predict+the+Severity+of+Acute+Kidney+Injury&rft.jtitle=Critical+care+%28London%2C+England%29&rft.au=Chawla%2C+Lakhmir+S&rft.au=Davison%2C+Danielle+L&rft.au=Brasha-Mitchell%2C+Ermira&rft.au=Koyner%2C+Jay+L&rft.date=2013-09-20&rft.pub=BioMed+Central+Ltd&rft.issn=1364-8535&rft.volume=17&rft_id=info:doi/10.1186%2Fcc13015&rft.externalDocID=A534778252 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1364-8535&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1364-8535&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1364-8535&client=summon |